Natco Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1995-01-01
- Employees
- 1K
- Market Cap
- $3.2B
- Website
- http://www.natcopharma.co.in
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Phase 2
Recruiting
- Conditions
- CarcinomaRecurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- NATCO Pharma Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05283226
- Locations
- 🇺🇸
Providence Medical Foundation -Fullerton, Fullerton, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Lynn Cancer Center, Boca Raton, Florida, United States